Scalable AAV Manufacturing Strategies
Dr. Xiao Pan
Director of ProBio, Platform R&D Department
2019，ProBio. Director of Platform R&D Dept.
2017，FUJIFILM-Diosynth Biotechnologies (UK). Principal scientist
2014，Synthon Biopharmaceuticals (NL). Senior scientist
2010-2016，Wageningen University(NL), Biotechnology/Bioengineering, Ph.D, MSc.
2017，FUJIFILM-Diosynth Biotechnologies (UK). Principal scientist
2014，Synthon Biopharmaceuticals (NL). Senior scientist
2010-2016，Wageningen University(NL), Biotechnology/Bioengineering, Ph.D, MSc.
Time
Topic
13:00-14:00 (GMT+8:00)
Dr. Xiao Pan, Director of ProBio, Platform R&D Department
Since the approval of the product Luxtura® using AAV as a vector in 2017, more and more clinical trials have been carried out rapidly, and various early clinical trial projects for rare diseases and a wide range of indications are under development. AAV based therapy has entered a golden age of rapid growth. There is also growing demand for commercial scalable AAV manufacturing due to its good safety, wide host range and low immunogenicity.
To meet the huge demand from the market, whether AAV vectors can be manufactured on a large scale is a key challenge.
To meet the huge demand from the market, whether AAV vectors can be manufactured on a large scale is a key challenge.
00:00
00:00
Related Service
